Evidence map›Paper›PMID 41193887›Full record

ArticleJournal of hematopathology2025

Validation and interpretation of the Triple A model in Turkish myeloproliferative neoplasm patients with a focus on overall and thrombosis free survival.

Mehmet Baysal, Sevil Sadri, Özgür Ömer Gül, Elif Köse, Serap Baysal, Vildan Gursoy

Abstract readValidation StudyMulticenter Study
PubMed Publisher
In one paragraph

Article in Journal of hematopathology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Mehmet BaysalDivision of Hematology, Department of Internal Medicine, Tekirdag Namık Kemal University, Tekirdag, Turkey. drmehmetbaysal@gmail.com.
Sevil SadriDivision of Hematology, Department of Internal Medicine, Istanbul Training and Research Hospital, Istanbul, Turkey.
Özgür Ömer GülDepartment of Internal Medicine, Bursa City Hospital, Bursa, Turkey.
Elif KöseDepartment of Internal Medicine, Bursa City Hospital, Bursa, Turkey.
Serap BaysalDepartment of Public Health, Tekirdag Namık Kemal University, Tekirdag, Turkey.
Vildan GursoyDivision of Hematology, Department of Internal Medicine, Bursa Uludag University, Bursa, Turkey.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe Triple A model has recently been developed and validated in essential thrombocythemia (ET) and polycythemia vera (PV). However, external validation in diverse populations remains unclear. PURPOSE: The purpose of this study was to externally validate the Triple A prognostic model in a Turkish cohort of patients with ET and PV.

methodsA retrospective analysis was conducted at two centers in Bursa, Türkiye, involving patients diagnosed with ET or PV under the World Health Organization (WHO) 2016/2022 criteria between 2014 and 2024.

resultsWhile the Triple A model has significantly separated the ET patients with a median follow-up of 47 months (p = 0.015), no significant difference was observed in PV patients in terms of survival (p = 0.87). For thrombosis-free survival (TFS), Fine and Gray's competing risk analysis showed a significant separation with the Triple A model in ET (p = 0.017).

conclusionWhile the Triple A model was validated as a practical prognostic tool in ET, it demonstrated limited utility in PV. Further multicenter studies are needed to refine risk stratification in PV.

Indexed as

Myeloproliferative DisordersPolycythemia VeraThrombocythemia, EssentialThrombosisAdultAgedAged, 80 and overDisease-Free SurvivalFemaleHumansMaleMiddle AgedPrognosisRetrospective StudiesTurkeyEssential thrombocythemiaMyeloproliferative neoplasmsPolycythemia veraTriple A

Identifiers

PMID41193887

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.